These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16401950)

  • 21. The future of drug product selection in health care and the role of the pharmacy and therapeutics committee.
    Cohen P
    Manag Care Interface; 2006 Dec; 19(12):15-6. PubMed ID: 17274477
    [No Abstract]   [Full Text] [Related]  

  • 22. Surveillance of drug adverse reactions.
    Campbell JS; Henderson IW
    Can Med Assoc J; 1972 Jun; 106(12):1285. PubMed ID: 5035130
    [No Abstract]   [Full Text] [Related]  

  • 23. Age: a growing P & T concern.
    Lipman AG
    Hosp Formul; 1983 May; 18(5):475. PubMed ID: 10260197
    [No Abstract]   [Full Text] [Related]  

  • 24. The liability issue in pediatric drug therapy.
    Rollerson C
    Hosp Formul; 1977 May; 12(5):328. PubMed ID: 10236477
    [No Abstract]   [Full Text] [Related]  

  • 25. [Reports on drug side effects for the period 1973-1974].
    Tidsskr Nor Laegeforen; 1975 Aug; 95(22):1243-7. PubMed ID: 1162667
    [No Abstract]   [Full Text] [Related]  

  • 26. Developing policy for handling investigational drugs.
    Ebel JA
    Hosp Manage; 1967 Aug; 104(2):58-64. PubMed ID: 6073958
    [No Abstract]   [Full Text] [Related]  

  • 27. [Responsibility for drug reactions].
    Naess K
    Nord Med; 1975 Mar; 90(3):65-6. PubMed ID: 1153254
    [No Abstract]   [Full Text] [Related]  

  • 28. [Available list of adverse effects].
    Liljestrand A
    Lakartidningen; 1976 Apr; 73(15):1397. PubMed ID: 1263655
    [No Abstract]   [Full Text] [Related]  

  • 29. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is the present concept of commissions for expedient pharmacotherapy rational?].
    Barcal M; Slunecko V; Svatek Z
    Cesk Zdrav; 1971 Jul; 19(7):274-8. PubMed ID: 5556742
    [No Abstract]   [Full Text] [Related]  

  • 31. [Reports of secondary effects].
    Ugeskr Laeger; 1974 Aug; 136(32):1822. PubMed ID: 4410753
    [No Abstract]   [Full Text] [Related]  

  • 32. The evolutionary role of the pharmacy and therapeutics committee in technology assessment.
    Mehr SR
    Manag Care Interface; 2006 Jan; 19(1):42-5. PubMed ID: 16453995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not for the pharmaceutical institute: Stake on clinical pharmacology. Regional rationalization is profitable].
    Lakartidningen; 1970 Jan; 67(5):483-6. PubMed ID: 5426359
    [No Abstract]   [Full Text] [Related]  

  • 34. Role playing using a simulated pharmacy and therapeutics committee model.
    Fletcher HP; Popovich NG
    Am J Pharm Educ; 1977 Aug; 41(3):282-5. PubMed ID: 10305978
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacotherapy--how to raise the standard?].
    Naess K
    Nord Med; 1972 Mar; 87(3):78-80. PubMed ID: 5027852
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacotherapeutic information explosion and medical practice].
    Dahlström H
    Lakartidningen; 1972 Sep; 69(40):4512-4. PubMed ID: 5072438
    [No Abstract]   [Full Text] [Related]  

  • 37. Should all trials have a data safety and monitoring committee?
    Cairns JA; Hallstrom A; Held P
    Am Heart J; 2001 Jan; 141(1):156-63. PubMed ID: 11136502
    [No Abstract]   [Full Text] [Related]  

  • 38. What guidelines should a P & T Committee consider for the handling of cytotoxic drugs?
    Mofenson HC; Caraccio TR
    Hosp Formul; 1988 Nov; 23(11):923-4. PubMed ID: 10290755
    [No Abstract]   [Full Text] [Related]  

  • 39. [Experiences in approving drugs].
    Schnieders B
    Internist (Berl); 1980 Jun; 21(6):325-32. PubMed ID: 7005169
    [No Abstract]   [Full Text] [Related]  

  • 40. [Create or strengthen the drug committee at a hospital].
    Bruneton C
    Med Trop (Mars); 2006 Dec; 66(6):569-72. PubMed ID: 17286023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.